Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BFLY NASDAQ:DCTH NASDAQ:OBIO NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$1.43+1.4%$1.88$0.90▼$4.98$354.95M2.453.84 million shs3.16 million shsDCTHDelcath Systems$10.36-1.1%$12.39$7.45▼$18.23$366.25M0.82852,871 shs434,276 shsOBIOOrchestra BioMed$2.57-3.4%$2.98$2.37▼$7.04$102.79M0.62395,890 shs238,661 shsTMCITreace Medical Concepts$6.89-0.9%$5.90$4.54▼$10.79$439.05M0.68364,595 shs653,868 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network+1.79%+7.12%-20.33%-39.53%+53.08%DCTHDelcath Systems-1.05%+3.50%-7.91%-39.42%+40.76%OBIOOrchestra BioMed-3.38%-5.17%-18.41%-11.38%-53.61%TMCITreace Medical Concepts-0.86%+12.40%+17.78%+2.53%+25.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFLYButterfly Network2.5074 of 5 stars3.43.00.00.01.12.50.6DCTHDelcath Systems2.6732 of 5 stars3.52.00.00.02.42.50.6OBIOOrchestra BioMed3.3926 of 5 stars3.65.00.00.03.02.50.0TMCITreace Medical Concepts2.5039 of 5 stars3.21.00.00.02.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFLYButterfly Network 2.75Moderate Buy$3.00109.78% UpsideDCTHDelcath Systems 3.00Buy$24.50136.49% UpsideOBIOOrchestra BioMed 3.20Buy$14.00444.75% UpsideTMCITreace Medical Concepts 2.33Hold$9.8342.72% UpsideCurrent Analyst Ratings BreakdownLatest OBIO, TMCI, DCTH, and BFLY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.008/8/2025TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$8.60 ➝ $6.508/8/2025TMCITreace Medical ConceptsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$9.00 ➝ $6.008/7/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $31.008/7/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.008/4/2025BFLYButterfly NetworkCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingPositive ➝ Positive$2.008/1/2025BFLYButterfly NetworkOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform7/1/2025BFLYButterfly NetworkCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.006/23/2025DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.00(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFLYButterfly Network$82.06M4.39N/AN/A$0.92 per share1.55DCTHDelcath Systems$37.21M9.74N/AN/A$3.00 per share3.45OBIOOrchestra BioMed$2.64M37.62N/AN/A$0.01 per share257.00TMCITreace Medical Concepts$209.36M2.08N/AN/A$1.55 per share4.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFLYButterfly Network-$72.49M-$0.28N/AN/AN/A-71.79%-30.53%-21.80%N/ADCTHDelcath Systems-$26.39M$0.05207.20N/AN/A3.18%6.91%5.80%N/AOBIOOrchestra BioMed-$61.02M-$1.83N/AN/AN/A-2,367.49%-289.42%-110.04%N/ATMCITreace Medical Concepts-$55.74M-$0.79N/AN/AN/A-23.01%-46.76%-23.35%11/4/2025 (Estimated)Latest OBIO, TMCI, DCTH, and BFLY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025OBIOOrchestra BioMed-$0.51-$0.50+$0.01-$0.50$0.78 million$0.84 million8/7/2025Q2 2025TMCITreace Medical Concepts-$0.29-$0.28+$0.01-$0.28$47.08 million$47.39 million8/6/2025Q2 2025DCTHDelcath Systems$0.02$0.07+$0.05$0.07$22.84 million$24.16 million8/1/2025Q2 2025BFLYButterfly Network-$0.07-$0.06+$0.01-$0.06$23.91 million$23.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFLYButterfly NetworkN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFLYButterfly NetworkN/A5.684.14DCTHDelcath SystemsN/A10.889.87OBIOOrchestra BioMed48.762.103.34TMCITreace Medical Concepts0.553.523.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFLYButterfly Network37.85%DCTHDelcath Systems61.12%OBIOOrchestra BioMed53.20%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipBFLYButterfly Network25.18%DCTHDelcath Systems17.40%OBIOOrchestra BioMed8.10%TMCITreace Medical Concepts27.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFLYButterfly Network460251.74 million188.35 millionOptionableDCTHDelcath Systems6034.98 million28.89 millionOptionableOBIOOrchestra BioMed438.64 million35.51 millionNot OptionableTMCITreace Medical Concepts25063.17 million45.66 millionOptionableOBIO, TMCI, DCTH, and BFLY HeadlinesRecent News About These CompaniesTreace Medical Concepts: Positive Q2 Earnings Call HighlightsAugust 12, 2025 | tipranks.comAnalysts Have Been Trimming Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target After Its Latest ReportAugust 12, 2025 | finance.yahoo.comTreace Medical Concepts (NASDAQ:TMCI) Releases Earnings Results, Beats Expectations By $0.01 EPSAugust 11, 2025 | marketbeat.comUBS Group Cuts Treace Medical Concepts (NASDAQ:TMCI) Price Target to $6.50August 10, 2025 | marketbeat.comArcadia Wealth Management Inc. Invests $1.76 Million in Treace Medical Concepts, Inc. (NASDAQ:TMCI)August 10, 2025 | marketbeat.comStifel Nicolaus Lowers Treace Medical Concepts (NASDAQ:TMCI) Price Target to $6.00August 10, 2025 | americanbankingnews.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comStifel Nicolaus Issues Pessimistic Forecast for Treace Medical Concepts (NASDAQ:TMCI) Stock PriceAugust 9, 2025 | marketbeat.comTreace Medical Concepts Inc (TMCI) Q2 2025 Earnings Call Highlights: Revenue Growth and ...August 8, 2025 | uk.finance.yahoo.comTreace Medical anticipates 7–10% revenue growth in 2025 while launching next-gen bunion solutionsAugust 8, 2025 | msn.comTreace Medical Concepts, Inc. (TMCI) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comTreace Medical (TMCI) Q2 Revenue Up 7%August 7, 2025 | fool.comTreace Medical Concepts (TMCI) Reports Q2 Loss, Beats Revenue EstimatesAugust 7, 2025 | zacks.comTreace Medical Concepts Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comTreace Medical to Host Investor Day Highlighting New Products on September 3, 2025August 7, 2025 | globenewswire.comTreace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical StudyAugust 5, 2025 | finance.yahoo.comGSA Capital Partners LLP Buys Shares of 66,790 Treace Medical Concepts, Inc. (NASDAQ:TMCI)August 4, 2025 | marketbeat.comTreace Medical Concepts (TMCI) to Release Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comLegato Capital Management LLC Purchases Shares of 56,220 Treace Medical Concepts, Inc. (NASDAQ:TMCI)July 26, 2025 | marketbeat.comKornitzer Capital Management Inc. KS Sells 161,525 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI)July 16, 2025 | marketbeat.comTreace Medical Concepts, Inc. Common Stock (TMCI) - NasdaqJuly 9, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBIO, TMCI, DCTH, and BFLY Company DescriptionsButterfly Network NYSE:BFLY$1.43 +0.02 (+1.43%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$1.43 0.00 (-0.01%) As of 08/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.Delcath Systems NASDAQ:DCTH$10.36 -0.11 (-1.05%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$10.32 -0.04 (-0.34%) As of 08/15/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Orchestra BioMed NASDAQ:OBIO$2.57 -0.09 (-3.38%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.57 +0.00 (+0.04%) As of 08/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Treace Medical Concepts NASDAQ:TMCI$6.89 -0.06 (-0.86%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$6.89 0.00 (0.00%) As of 08/15/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.